| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07174908 | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First… | Non-Small Cell Lung Cancer | Recruiting |
| Phase 2 | |||
| NCT06014528 | IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in… | Ovarian Cancer Recurrent | Recruiting |
| Phase 1/2 | |||
| NCT05827796 | IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | Pancreatic Cancer | Recruiting |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | NSCLC | Recruiting |
| NCT06030258 | IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Small Cell Lung Cancer Extensive Stage | Recruiting |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive… | Solid Tumor Cancer | Recruiting |
| NCT05551507 | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian… | Platinum-resistant Ovarian Cancer | Recruiting |
| NCT06166836 | a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C… | Solid Tumor | Active, Not Recruiting |
| Phase 1 | |||
| NCT07596381 | FAK Inhibitor in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not Yet Recruiting |